United States: BakerHostetler FDA And Pharmacy Weekly Digest - December 3, 2018

Food/Dietary Supplements

FDA Investigates Multiple Foodborne Illness Outbreaks – The FDA and the CDC have launched a multistate investigation of a Salmonella Concord outbreak linked to certain tahini products. FDA advised consumers not to eat these imported products. In addition, FDA continues to investigate the E. coli outbreak related to romaine lettuce.

FDA Executes MOU With China – FDA issued a reminder that U.S. establishments that are on the dairy, seafood and infant formula export lists for China must obtain third-party certification of compliance with applicable Chinese laws by June 15, 2019, to maintain continued access to the Chinese market. In addition, the FDA issued its updated guidance titled "Guidance for Industry: Establishing and Maintaining a List of U.S. Milk and Milk Product, Seafood, Infant Formula, and Formula for Young Children Manufacturers/Processors with Interest in Exporting to China."

FDA Issues Warning About Certain Dietary Supplements – The FDA warned dietary supplement marketers that market products containing tianeptine, because a number of these products make claims that the products treat opioid use disorder and pain and anxiety. This warning resulted from reports of serious adverse events associated with tianeptine-containing products.


FDA Warns of Hidden Ingredients in Drug Products – The FDA issued two public notifications about products containing hidden ingredients. FDA warned consumers not to purchase a weight-loss product because it contains sibutramine and phenolphthalein, which have been removed from the market due to safety concerns. FDA also warned consumers not to purchase a product promoting sexual enhancement because it contains undisclosed sildenafil, the same ingredient contained in Viagra.

Large Manufacturer Issues Voluntary Nationwide Recall – A manufacturer issued a voluntary nationwide recall of sodium chloride injections (USP, 0.9%). The "product insert states that stoppers for both the 10mL and the 20mL vials do not contain natural rubber latex; the tray label for the two vial sizes and the vial label for the 20mL vial also state that the stoppers do not contain latex. The product is being recalled because the stoppers contain natural rubber latex."

FDA Announces Grants for Animal Drugs – The FDA opened applications for grants in support of new animal drug development. The grants are focused on treatment of uncommon diseases in major species.

Medical Devices

FDA Issues Draft Guidance Documents Related to Blood Glucose Monitoring – The FDA published two revised draft guidance documents. The guidance documents address design considerations and recommended device standards.

FDA Issues Draft Guidance Documents on CLIA Waiver Applications – The FDA published two draft guidance documents focused on helping manufacturers of in vitro diagnostic devices seeking Clinical Laboratory Improvement Amendments (CLIA) waivers. FDA is also hosting a webinar related to these guidance documents.

FDA Asks for Feedback to Inform Draft Guidance – The FDA is requesting input on its patient engagement discussion document issued after its October Patient Engagement Advisory Committee meeting. The discussion document focuses on patient engagement in medical device clinical trials. Comments can be submitted until Jan. 8, 2019.

FDA Announces Modernization of 510(k) Process – The FDA issued a joint statement from the commissioner and director of the Center for Devices and Radiological Health indicating that the "framework [FDA] propose[s] is aimed at efficiently advancing beneficial technology to patients, while solidifying FDA's gold standard for safety." The types of medical devices appropriate for this pathway either use advances in technology or meet more modern safety and performance criteria.

FDA Issues Medical Device Enforcement and Quality Report – The FDA recently released a report detailing its enhanced oversight of medical device firms through increased inspections, development of the Medical Device Single Audit program and its "targeted risk-based approach to addressing concerns with specific devices."


FDA Warns Company Selling Certain E-liquids – The FDA issued a warning letter to a company for selling e-liquids that resemble kid-friendly food items. This is part of the FDA's plan to continue to protect children from tobacco products.


HHS Publishes 340B Drug Rule – HHS published the "340B Drug Pricing Ceiling Price and Manufacturer Civil Monetary Penalties Regulation." HHS changed the effective date of this regulation to Jan. 1, 2019.

CMS Proposes Changes to Medicare Advantage and Part D – CMS announced changes to both Medicare Advantage and Part D to lower drug prices. As part of the plan, CMS announced that it plans to allow step therapy for Medicare Advantage plans and "allow MA plans to offer beneficiaries the drug in Part B, which covers physician-administered drugs, that is most cost-effective before progressing to other options." CMS is also considering a plan "to require that the price a beneficiary pays at the pharmacy counter reflects the lowest possible cost, so beneficiaries receive the maximum benefit. If adopted, this change would lower cost sharing for beneficiaries by about $12 to $15 billion over 10 years." The proposed rule also addresses DIR fees.

Georgia Insurance Commissioner Demands Protections Prior to Merger – The Georgia insurance commissioner won a number of protections in order for the merger of CVS and Aetna to gain approval. Such protections include the requirement that CVS/Aetna allow non-CVS healthcare providers (including pharmacies) to join its networks.

US and China Come to Agreement on Fentanyl – News outlets report that President Trump and President Xi came to an agreement over the classification and treatment of Fentanyl in China. If China does in fact go through with the proposed changes, manufacturers, compounders, and other healthcare providers could see potential changes in the availability of the substance.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Sign Up
Gain free access to lawyers expertise from more than 250 countries.
Email Address
Company Name
Confirm Password
Mondaq Newsalert
Select Topics
Select Regions
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions